Rivpra Formulation commits Rs 15 crore to new Oteria plant
Rivpra Formulation is investing Rs 15 crore in a new Oteria manufacturing plant, targeting a production capacity of one million units per month, as reported by ET Retail on 15 September 2026. No further details on location, construction timeline or appointed contractors were available at the time of reporting.
| Detail | Information |
|---|---|
| Promoter | Rivpra Formulation |
| Project | New Oteria plant |
| Announced investment | Rs 15 crore |
| Target capacity | 1 million units per month |
| Source | ET Retail, reported 15 September 2026 |
Project scope as reported
The available information is limited to what ET Retail published on 15 September 2026. The headline confirms the investment figure of Rs 15 crore and the targeted monthly output of one million units for the Oteria product line. No breakdown of the capital expenditure, appointed contractors, equipment suppliers or regulatory approvals has been disclosed in the available source material.
Where pharmaceutical manufacturing investment is concentrated in India
Projects India tracks 1,787 live projects in the Drugs and Pharmaceuticals sub-sector, with 17 added to the database in the last 90 days alone. The geographic distribution of those projects shows Gujarat leading with 605 tracked projects, followed by Telangana at 243, Andhra Pradesh at 231, Karnataka at 214, Maharashtra at 166 and Himachal Pradesh at 59.
This spread reflects long-established pharmaceutical clusters in western and southern India, as well as the continued expansion of dedicated pharma zones in states such as Telangana and Andhra Pradesh. Suppliers and equipment providers looking for recurring opportunities will find those six states account for the largest share of active pipeline volume.
Pipeline stage breakdown: where projects stand
Across all 1,787 tracked projects in the sub-sector, the stage breakdown is as follows: 635 are under approvals, 359 have commenced construction, 323 are completed, 137 have received approvals and are pending construction start, 137 are on hold, and 98 are at the planning stage. The concentration of projects in the approvals and construction phases indicates a pipeline that continues to convert from intent to active execution.
Recent additions to the tracked pipeline illustrate the range of investment sizes in play. Projects currently under approvals include a Rs 7.5 crore API and intermediates manufacturing project by Dwiraaju Pharma Private Limited in Ahmedabad, Gujarat, and an Rs 18 crore dextrose saline and medicines manufacturing unit expansion by Guddodgi Pharmaceutical Distributors in Vijayapura, Karnataka. At the larger end, Virupaksha Organics Limited has a Rs 1,225 crore bulk drugs and drug intermediates project in Kurnool, Andhra Pradesh, at the planning stage. Meanwhile, Suncare Formulation Private Limited in Dehradun, Uttarakhand has a Rs 55 crore gelatin capsules and ointments expansion that has entered construction. The full tracked projects listing provides deeper detail across all stages and geographies.
What this means for suppliers and contractors
For suppliers of formulation manufacturing equipment, cleanroom systems and packaging lines, the Rivpra Formulation announcement represents an early-stage opportunity to engage with a promoter building new capacity. At Rs 15 crore, the project falls within the mid-scale range that is typical of a significant portion of the sub-sector pipeline, where procurement decisions are often made quickly and by a small internal team rather than through extended tendering processes.
The broader pipeline data reinforces where sustained demand is being generated. With 635 projects under approvals nationally, a sizeable volume of formulation, API and intermediates projects is approaching the procurement window. Gujarat, Telangana and Andhra Pradesh collectively host the largest shares of this pipeline, making them priority territories for sales and business-development activity. Contractors with experience in pharmaceutical-grade civil and mechanical work will find ongoing demand across these clusters as projects move from the approvals stage into construction. There are currently no open India tenders recorded under Industrial Projects in this sub-sector, but the volume of projects in pre-construction stages suggests tender activity is likely to follow. Readers can monitor the live tenders listing for updates as projects progress.
Frequently asked questions
How much is Rivpra Formulation investing in its new Oteria plant?
Rivpra Formulation is investing Rs 15 crore in a new Oteria plant. The company is targeting a monthly production capacity of one million units. This was reported by ET Retail on 15 September 2026. No further project details were available in the source material.
How many pharmaceutical manufacturing projects are tracked in India?
Projects India tracks 1,787 live projects in the Drugs and Pharmaceuticals sub-sector across India, with 17 added in the last 90 days. Gujarat leads with 605 projects, followed by Telangana at 243 and Andhra Pradesh at 231.
Which states have the most pharmaceutical projects under construction in India?
Across all tracked Drugs and Pharmaceuticals projects, 359 are at the construction-started stage nationally. Gujarat, Telangana, Andhra Pradesh and Karnataka host the largest shares of the overall sub-sector pipeline and are likely to account for a significant portion of active construction work.
